Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
Berger, Stefan P. 1; Sommerer, Claudia 2; Witzke, Oliver 3,4; Tedesco, Helio 5; Chadban, Steve 6; Mulgaonkar, Shamkant 7; Qazi, Yasir 8; de Fijter, Johan W. 9; Oppenheimer, Federico 10; Cruzado, Josep M. 11; Watarai, Yoshihiko 12; Massari, Pablo 13; Legendre, Christophe 14; Citterio, Franco 15; Henry, Mitchell 16; Srinivas, Titte R. 17; Vincenti, Flavio 18; Gutierrez, Maria Pilar Hernandez 19; Marti, Ana Maria 19; Bernhardt, Peter 19; Pascual, Julio *,20; the TRANSFORM investigators
[Article]
American Journal of Transplantation.
19(11):3018-3034, November 2019.
(Format: HTML, PDF)